

Drug Corner

Remdesivir in Mild, Non-hospitalized high-risk cases

- PINETREE trial (Nejm, Dec 2021) has set a new platform to use Remdesivir mild-to-moderate COVID-19 with high-risk situations as out-patient basis.
- It reduced serious outcomes among unvaccinated high-risk COVID-19 patients when given during the early symptomatic period outside the hospital.
- This tests the concept that Remdesivir is more likely to have a clinically meaningful benefit before hospitalization than later in the disease course.
- A 3-day course of the IV antiviral cut hospitalization for COVID-19 or death from any cause by a relative 87%.
- It can be a better choice where outpatient skilled infusion facilities even at home
- Dose: **Remdesivir 200 mg** IV on Day 1, followed by **Remdesivir 100 mg** IV daily on Days 2 and 3, initiated as soon as possible and within 7 days of symptom onset in those aged ≥ 12 years and weighing ≥ 40 kg diabetes.

*Dr. N. K. Singh, MD, FICP, Diabetologist Physician,
Dhanbad*